3.58
-0.2(-5.29%)
Currency In USD
| Previous Close | 3.78 |
| Open | 3.9 |
| Day High | 3.9 |
| Day Low | 3.51 |
| 52-Week High | 6.5 |
| 52-Week Low | 1.6 |
| Volume | 82,408 |
| Average Volume | 215,479 |
| Market Cap | 123.65M |
| PE | -3.81 |
| EPS | -0.94 |
| Moving Average 50 Days | 3.76 |
| Moving Average 200 Days | 2.76 |
| Change | -0.2 |
If you invested $1000 in Genelux Corporation (GNLX) since IPO date, it would be worth $582.11 as of March 14, 2025 at a share price of $3.58. Whereas If you bought $1000 worth of Genelux Corporation (GNLX) shares 1 year ago, it would be worth $574.64 as of March 14, 2025 at a share price of $3.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Genelux Corporation Announces New Chief Financial Officer
GlobeNewswire Inc.
Feb 03, 2025 11:45 AM GMT
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effectiv
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
GlobeNewswire Inc.
Dec 13, 2024 12:01 PM GMT
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virt
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 06, 2024 9:01 PM GMT
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will discuss clinical-sta